KORA SAUDE (KRSA3) Main Indicators
Basic Data - KRSA3
| Company | KORA SAUDE |
| Corporate Name | KORA SAÚDE PARTICIPAÇÕES S.A |
| Registration Status | ATIVO |
| Issuer Status | FASE OPERACIONAL |
| Listing Segment | Tradicional - BOVESPA |
| Activity | Holding de instituições não financeiras com fim a prestação de serviços de atenção a saúde humana. limpeza. planos de saúde. bem como outras atividades secundárias como aluguel de imóveis. |
| Share | KRSA3 |
| Quote Date | 04/01/2025 |
| Share Type | ON |
| Last Closing | R$ 8.85 |
| Quotation Factor | 1 Share |
| Financial Volume | R$ 7.96 thousand |
| Last Statement | DFP - 12/31/2024 |
| Sector | Saúde |
| Subsector | Serv.Méd.Hospit..Análises e Diagnósticos |
| Segment | Serv.Méd.Hospit..Análises e Diagnósticos |
| Participation Indexes | IGC, IGNM, ITAG |
| Updated 04/02/2025 | |
Relative Prices - KRSA3
| Price/Earnings | -3.86 |
| Price/SBV | 0.84 |
| Price/Net Sales | 0.30 |
| Price/CFO | -6.12 |
| Price/FCF | -4.30 |
| Price/Total Assets | 0.14 |
| Price/EBIT | 2.57 |
| Price/Working Capital | 1.01 |
| Price/NCAV | -0.21 |
| EV/EBIT | 12.84 |
| EV/EBITDA | 7.83 |
| EV/Net Sales | 1.51 |
| EV/CFO | -30.63 |
| EV/FCF | -21.52 |
| EV/Total Assets | 0.72 |
| Company Market Cap | R$ 684.41 M |
| Enterprise Value | R$ 3.42 B |
| Current Financial Statement Date | 12/31/2024 |
| Current Share Price | R$ 8.85 |
| Share Price Date | 04/01/2025 |
| Dividend Yield | 0.00% |
| Updated 04/02/2025 | |
Income Statement - KRSA3
| Net Revenue | R$ 2.27 B |
| Gross Result | R$ 454.28 M |
| EBIT | R$ 266.59 M |
| Depreciation and Amortization | - R$ 170.73 M |
| EBITDA | R$ 437.32 M |
| Net Profit | - R$ 177.28 M |
| Net Profit/Share | - R$ 0.00 |
| Updated 03/31/2025 | |
| Net Revenue | R$ 556.45 M |
| Gross Result | R$ 113.38 M |
| EBIT | R$ 57.24 M |
| Depreciation and Amortization | - R$ 57.43 M |
| EBITDA | R$ 114.68 M |
| Net Profit | - R$ 104.73 M |
| Profit/Share | - R$ 0.00 |
| Updated 03/31/2025 | |
Price and Volume Behavior - KRSA3
| Lowest Price 52 weeks | R$ 4.24 |
| Highest Price 52 weeks | R$ 8.92 |
| Variation 2025 | 8.06% |
| Variation 1 year | 7.93% |
| Variation 2 years(total) | -13.24% |
| Variation 2 years(yearly) | -6.83% |
| Variation 3 years(total) | -74.71% |
| Variation 3 years(yearly) | -36.74% |
| Variation 4 years(total) | - |
| Variation 4 years(yearly) | - |
| Variation 5 years(total) | - |
| Variation 5 years(yearly) | - |
| Average Daily Volume (3 months) | R$ 521.55 thousand |
| Updated 04/02/2025 | |
Returns and Margins - KRSA3
| Return on Initial Tangible Capital | 8.98% |
| Return on Initial Invested Capital | 5.22% |
| Pre-Tax Return on Initial Tangible Capital | 13.61% |
| Pre-Tax Return on Initial Invested Capital | 7.91% |
| Return on Initial Shareholder´s Equity | -17.97% |
| Return on Initial Asset | -3.77% |
| Gross Margin | 20.03% |
| Net Margin | -7.82% |
| EBIT Margin | 11.75% |
| EBITDA Margin | 19.28% |
| Initial Asset Turnover | 0.48 |
| Financial Leverage | 5.87 |
| Liabilities/Net Worth | 4.87 |
| Net Debt/EBITDA | 6.26 |
| Updated 03/31/2025 | |
Balance Sheet - KRSA3
| Cash and Cash Equivalents | R$ 252.68 M |
| Total Assets | R$ 4.78 B |
| Short-Term Debt | R$ 211.49 M |
| Long-Term Debt | R$ 2.78 B |
| Gross Debt | R$ 2.99 B |
| Net Debt | R$ 2.74 B |
| Shareholder´s Equity | R$ 813.46 M |
| Share Book Value | R$ 0.01 |
| Common Shares | 77,334,806,000 |
| Preferred Shares | 0 |
| Total | 77,334,806,000 |
| Common Shares in Treasury | 430,063,000 |
| Preferred Shares in Treasury | 0 |
| Total in Treasury | 430,063,000 |
| Common Shares (Except Treasury) | 76,904,743,000 |
| Preferred Shares (Except Treasury) | 0 |
| Total (Except Treasury) | 76,904,743,000 |
| Updated 03/31/2025 | |
Cash Flow - KRSA3
| Operating Cash Flow | - R$ 111.76 M |
| Cash Flow from Investments | - R$ 79.27 M |
| Financing Cash Flow | R$ 83.85 M |
| Increase (Reduction) in Cash and Equivalents | - R$ 107.18 M |
| Updated 03/31/2025 | |
| Operating Cash Flow | R$ 22.44 M |
| Cash Flow from Investments | - R$ 2.81 M |
| Financing Cash Flow | R$ 59.95 M |
| Increase (Reduction) in Cash and Equivalents | R$ 79.58 M |
| Updated 03/31/2025 | |
Experimental - KRSA3
| CAPEX 3 months | - R$ 13.06 M |
| Free Cash Flow 3 months | R$ 9.38 M |
| CAPEX 12 months | - R$ 47.30 M |
| Free Cash Flow 12 months | - R$ 159.06 M |
| Updated 03/31/2025 | |